Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice

@article{Edrei2012ImprovedEO,
  title={Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice},
  author={Y. Edrei and E. Gross and N. Corchia and R. Abramovitch},
  journal={British Journal of Cancer},
  year={2012},
  volume={107},
  pages={658 - 666}
}
  • Y. Edrei, E. Gross, +1 author R. Abramovitch
  • Published 2012
  • Medicine
  • British Journal of Cancer
  • Background:The poor prognosis of patients with colorectal-cancer liver metastases (CRLM) and the insufficiency of available treatments have raised the need for alternative curative strategies. We aimed to assess the therapeutic potential of TL-118, a new anti-angiogenic drug combination, for CRLM treatment, in a mouse model.Methods:The therapeutic potential of TL-118 was evaluated and compared with B20-4.1.1 (B20; anti-VEGF antibody) and rapamycin in CRLM-bearing mice. Tumour progression and… CONTINUE READING
    13 Citations
    TL-118—anti-angiogenic treatment in pancreatic cancer: a case report
    • 7
    • PDF
    IL‐33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis
    • 71
    Anti-angiogenic effect of rapamycin in mouse oxygen-induced retinopathy is mediated through suppression of HIF-1alpha/VEGF pathway.
    • PDF
    Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
    • 45
    • PDF

    References

    SHOWING 1-10 OF 55 REFERENCES
    Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
    • 1,514
    • PDF
    Angiogenesis and hepatic colorectal metastases.
    • 9
    • PDF
    Suppression of primary tumor growth in a mouse model of human neuroblastoma.
    • 41
    Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab
    • 39
    Metronomic chemotherapy: new rationale for new directions
    • 485
    • PDF
    Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    • 654
    Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    • 1,594
    Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.
    • 104
    Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma
    • 50